Skip to main content

213 publications

Name Date Type Actions

ANNUAL RESULTS 2023 (slideshow)

01.2023 Highlights
02.2023 Consolidated financial statements
03.Strategy and outlook

20/03/2024 Annual Report

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

20/03/2024 Public releases

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

24/01/2024 Public releases

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

26/10/2023 Public releases

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

07/09/2023 Public releases

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

20/04/2023 Public releases

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

13/04/2023 Public releases

[VIDEO] Présentation des résultats annuels 2022 -French

Présentation analystes & investisseurs - 23 Mars 2023

23/03/2023 Annual Report

ANNUAL RESULTS 2022 (slideshow)

01.2022 Highlights
02.2022 Consolidated financial statements
03.Strategy and outlook

23/03/2023 Annual Report

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

23/03/2023 Public releases